Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
Kedrion is the largest player in Italy and one of the top 5 worldwide. The company operates through 4 manufacturing sites in Italy, US and Hungary and 26 plasma collection centers, and has over 2,500 employees.
Kedrion
INVESTMENT DATE
November 2019
Company Profile
The Investment
The FSI investment, in partnership with the Marcucci family, has the objective to further accelerate the company international growth plan.